The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis

Thumbnail Image

Files

65.pdf (8.38 MB)

Date

2025-06

Document type

journal article

Collections

Investigación
Total downloads1
Total views1
Bibliographic managers

Authors

Bruna-Mejías, Alejandro, Silva-Bravo, Vicente, Moyano Valarezo, Laura, Delgado-Retamal, María Fernanda, Nazar-Izquierdo, Diego, Aguilar-Aguirre, Isidora, Nova-Baeza, Pablo, Orellana-Donoso, Mathias, Suazo-Santibáñez, Alejandra, Gutiérrez-Espinoza, Héctor, Sanchis Gimeno, Juan, Bastidas-Caldes, Carlos, Valenzuela Fuenzalida, Juan José

Publisher

Multidisciplinary Digital Publishing Institute (MDPI)

URI

https://repositorio.udla.cl/handle/udla/2278

DOI

https://doi.org/10.3390/ph18060795

Keywords

bevacizumab pharmaceutical, bevacizumab therapy, glioblastoma, glioma, multiform glioblastoma

Citation

Bruna-Mejías, Alejandro; Silva-Bravo, Vicente; Moyano Valarezo, Laura; Delgado-Retamal, María Fernanda; Nazar-Izquierdo, Diego; Aguilar-Aguirre, Isidora; Nova-Baeza, Pablo; Orellana-Donoso, Mathias; Suazo-Santibáñez, Alejandra; Gutiérrez-Espinoza, Héctor; Sanchis Gimeno, Juan; Bastidas-Caldes, Carlos; Valenzuela Fuenzalida, Juan José (2025). The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis. Pharmaceuticals, 18(6), 795. https://doi.org/10.3390/ph18060795

Abstract

Background: A glioblastoma (GBM) is a type of tumor originating from the glial brain cells, the astrocytes, and thus belongs to the astrocytoma group. Bevacizumab (BV) is a treatment for GBM. BV is th...

Endorsement

Review

Supplemented By

Referenced By

Creative Commons license

Creative Commons Attribution 4.0 International
Except where otherwised noted, this item's license is described as Creative Commons Attribution 4.0 International
Usage statistics
01345
Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26